Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.93 |
| ▸ | FDPS | P14324 | 14/20 | 0.47 |
| ▸ | PGK1 | P00558 | 1/20 | 0.45 |
| ▸ | PGK2 | P07205 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 8/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etidronic Acid SCHEMBL18607 | 0.96 | LMNA (1.00) | LMNAFDPSPGK1PGK2CA2 | |
| Etidronic Acid SCHEMBL10532992 | 0.96 | LMNA (1.00) | LMNAFDPSPGK1PGK2CA2 | |
| Etidronic Acid SCHEMBL3130855 | 0.93 | LMNA (0.93) | LMNAFDPSPGK1PGK2CA2 | |
| Etidronic Acid SCHEMBL1924063 | 0.93 | LMNA (0.93) | LMNAFDPSPGK1PGK2CA2 | |
| Etidronic Acid SCHEMBL579129 | 0.93 | LMNA (0.93) | LMNAFDPSPGK1PGK2CA2 | |
| Etidronic Acid SCHEMBL10706705 | 0.93 | LMNA (0.93) | LMNAFDPSPGK1PGK2CA2 | |
| Etidronic Acid SCHEMBL10524952 | 0.93 | LMNA (0.93) | LMNAFDPSPGK1PGK2CA2 | |
| Etidronic Acid SCHEMBL6141145 | 0.93 | LMNA (0.93) | LMNAFDPSPGK1PGK2CA2 | |
| Etidronic Acid SCHEMBL3896726 | 0.93 | LMNA (0.93) | LMNAFDPSPGK1PGK2CA2 | |
| Etidronic Acid SCHEMBL17580248 | 0.93 | LMNA (0.93) | LMNAFDPSPGK1PGK2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101600707-A | Urea compounds for the treatment of cancer | BAYER PHARMACEUTICALS CORP (US) | 2009-12-09 | — | — | CN | claimed |
| CN-101010315-A | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER PHARMACEUTICALS CORP (US) | 2007-08-01 | — | — | CN | claimed |
| CN-118359610-A | MENIN-MLL interaction inhibitors | 生命医药有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-117999363-A | Compositions and methods for cell-free DNA epigenetic gastrointestinal cancer detection and treatment | 希望之城 | 2024-05-07 | — | — | CN | disclosed |
| CN-112204009-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117979997-A | Anti-receptor-associated tyrosine kinase (RYK) antibodies and uses thereof | 加利福尼亚大学董事会 | 2024-05-03 | — | — | CN | disclosed |
| CN-117899029-A | High surface area lyophilized compositions containing arsenic for oral administration in patients | 希洛斯医药品股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117903308-A | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies | 综合医院公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117794932-A | Pyridopyrimidine derivatives useful as WEE1 kinase inhibitors | 阿普里治疗股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117769443-A | Fibroblast activation protein inhibitor and use thereof | 3B制药有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-117642168-A | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20120095443-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2419091-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | The Board of Regents of The University of Texas System (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2355864-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | The Board of Regents of The University of Texas System (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010120817-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100152699-A1 | Nanochanneled Device and Related Methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010056986-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-05-20 | — | — | WO | disclosed |
| CN-101600707-A | Urea compounds for the treatment of cancer | BAYER PHARMACEUTICALS CORP (US) | 2009-12-09 | — | — | CN | disclosed |
| CN-101010315-A | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER PHARMACEUTICALS CORP (US) | 2007-08-01 | — | — | CN | disclosed |
| WO-2006065234-A1 | USE OF LIPID AND HYDROGEL VEHICLES FOR TREATMENT AND DRUG DELIVERY | UNIVERSITY OF PITTSBURGH (US) | 2006-06-22 | — | — | WO | disclosed |